Clinical trials · New York, NY
Major Depressive Disorder clinical trials in New York
We’re tracking 57 recruiting major depressive disorder studies with a site in or near New York — including Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT05925322Recruiting
Social reward therapy for depression-related suicidal thoughts
This study looks at whether “social reward” psychotherapy can change brain activity and reduce suicidal thoughts in adults ages 50–80 who also have major depression. You may be offered psychotherapy along with brain scans to see how your brain responds over time.
New York, New YorkAges 50–80 - NCT06966401RecruitingPhase 3
Long-term safety study of a new depression treatment
This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.
New York, New YorkAges 18 years+ - NCT05850689RecruitingPhase 3
Lumateperone add-on for major depression that didn’t improve
This study tests whether adding lumateperone to an antidepressant helps adults with major depressive disorder (MDD) who haven’t improved enough after trying at least two different antidepressants. It may help reduce depressive symptoms more than antidepressants alone.
New York, New YorkAges 18–65 - NCT06938841Recruiting
Maintenance rTMS for depression
This study tests whether ongoing rTMS treatments can help people who already improved after an initial round of rTMS for depression. It aims to keep the benefits going and prevent relapse.
New York, New YorkAges 18–80 - NCT07412756RecruitingPhase 3
Brenipatide for major depressive disorder
This trial tests a new medication, Brenipatide, to see if it helps people with major depression who are already on a stable treatment. You would need to inject the study drug yourself and complete questionnaires.
New York, New YorkAges 18–75 - NCT07493317RecruitingPhase 2
Tocilizumab for depression with inflammation
This trial tests a medication called tocilizumab, which targets inflammation, to see if it can improve symptoms of major depression in people with signs of inflammation. You may be eligible if you have depression with a high monocyte count and significant loss of interest or pleasure.
New York, New YorkAges 18–70 - NCT06559306RecruitingPhase 3
Seltorexant for depression with insomnia symptoms
This trial tests if adding seltorexant to your current antidepressant can improve depression and sleep problems. It is for people with major depressive disorder who still have symptoms, especially insomnia, despite trying at least one antidepressant.
New York, New YorkAges 18–74 - NCT07716098RecruitingPhase 3
Esketamine nasal spray for treatment-resistant depression
This study tests esketamine nasal spray versus a placebo in adults with depression that has not improved after trying at least two other antidepressants. It aims to see if the spray can help when standard pills have not worked.
New York, New YorkAges 18 years+ - NCT06605105Enrolling by invitationPhase 3
Long-term extension trial of CYB003 for depression
This long-term study is for people who already completed an earlier trial of the experimental drug CYB003 for major depression and who stayed on their regular antidepressant. It looks at the safety and effects of taking CYB003 again over many months.
New York, New YorkAges 18–85 - NCT06830044RecruitingPhase 3
Adding an experimental drug for major depression
This trial tests if adding a new medicine called milsaperidone can help people with major depression who haven't gotten enough relief from their current antidepressant. It aims to see if the combination works better than the antidepressant alone.
New York, New YorkAges 18–65 - NCT07745374Recruiting
Deep brain stimulation for bipolar depression
This study tests whether deep brain stimulation (DBS), a surgical treatment that uses electrical pulses to target specific brain areas, is safe and feasible for people with bipolar depression that hasn't improved with other treatments. It may offer a new option for those who have exhausted standard therapies.
New York, New YorkAges 22–70 - NCT06911112RecruitingPhase 3
A new pill for depression when current treatment isn't working well enough
This trial tests an investigational medication (NBI-1065845) added to your current antidepressant to see if it can improve depressive symptoms. It is for people with moderate to severe depression who have not fully responded to their current antidepressant.
New York, New YorkAges 18 years+ - NCT06922110Enrolling by invitationPhase 3
Long-term study of azetukalner for depression
This study is for people who already completed a previous trial of azetukalner for major depressive disorder. It tests the long-term safety and effects of continuing the medication.
New York, New YorkAges 18 years+ - NCT06823024Enrolling by invitation
Using speech patterns to predict treatment response in depression, PTSD, or bipolar disorder
This study tests if a computer algorithm can analyze your speech to predict how well you will respond to treatments like TMS or Spravato. It aims to create a simple tool that helps doctors choose the right treatment for you.
New York, New YorkAges 18–68 - NCT07076407RecruitingPhase 3
Testing a new antidepressant pill for depression
This study tests an experimental oral pill called azetukalner against a placebo to see if it safely reduces symptoms of major depressive disorder. It is for adults who are currently in a depressive episode lasting 6 weeks to 2 years and have not already tried multiple antidepressants that failed.
New York, New YorkAges 18–74 - NCT05757791RecruitingPhase 2
Testing an SGLT2 diabetes drug for depression
This Phase 2 trial tests whether an SGLT2 medicine (like empagliflozin) can reduce symptoms of major depression. It may help people with moderate-to-severe depression who are otherwise eligible for the study.
New York, New YorkAges 18–65 - NCT06559826RecruitingPhase 2
Ketamine therapy with or without talk for depression
This study compares ketamine alone to ketamine combined with psychotherapy for treating depression. It may help if you have moderate to severe depression and want to see if adding talk therapy improves results.
New York, New YorkAges 18–90 - NCT06963021RecruitingPhase 3
Study of NBI-1065845 for depression that hasn't fully responded to treatment
This trial tests an investigational drug called NBI-1065845 added to your current antidepressant. It is for people with moderate to severe depression or persistent depressive disorder who have not improved enough with oral antidepressants alone.
New York, New YorkAges 18 years+ - NCT06633016RecruitingPhase 2
ABX-002 for major depression (add-on treatment)
This trial tests a new medication called ABX-002 as an add-on to your current antidepressant. It's for people with moderate to severe depression who haven't gotten enough help from their current antidepressant alone.
New York, New YorkAges 18–65 - NCT06213324RecruitingPhase 4
Ketamine's effects on brain circuits in depression
This trial studies how ketamine affects brain circuits in people with depression compared to healthy volunteers. It involves a single infusion of ketamine and brain scans before and after.
New York, New YorkAges 18–65 - NCT07276997RecruitingPhase 2
Study of Icalcaprant for major depressive disorder
This trial tests an oral medication called icalcaprant for adults with major depressive disorder (MDD). It aims to see if the drug can reduce depression symptoms and what side effects may occur.
New York, New YorkAges 18–65 - NCT05773755Recruiting
Brain stimulation surgery for treatment-resistant depression
This trial studies whether deep brain stimulation (DBS)—a surgically placed brain device—can reduce severe, long-lasting depression that hasn’t responded to many treatments. It may help people whose depression has persisted despite trying multiple antidepressant and other evidence-based therapies.
New York, New YorkAges 25–70 - NCT06592833RecruitingPhase 2
Psilocybin with or without pimavanserin for depression
This study tests whether combining psilocybin (a psychedelic substance) with pimavanserin (a medication that may help reduce side effects) works better than psilocybin alone for treating major depressive disorder. It may help people who have not responded well to other treatments.
New York, New YorkAges 21–80 - NCT07484217RecruitingPhase 3
Testing solriamfetol for depression with daytime sleepiness
This study tests if the drug solriamfetol can help people with major depression who also feel very tired during the day. It aims to improve both mood and daytime sleepiness.
New York, New YorkAges 18–65
Hear when a new Major Depressive Disorder trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Major Depressive Disorder trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting major depressive disorder studies listed above.
- Icahn School of Medicine at Mount Sinai · 6 studies
- Bio Behavioral Health · 3 studies
- Bioscience Research · 3 studies
- Fieve Clinical Research, Inc · 3 studies
- IMA Clinical Research Manhattan · 3 studies
- Neurocrine Clinical Site · 3 studies
- Adams Clinical Harlem · 2 studies
- Integrative Clinical Trials · 2 studies
What taking part in a major depressive disorder study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting major depressive disorder studies in New York.
Common questions
- Are there major depressive disorder clinical trials near New York?
- Yes. We're currently tracking 57 recruiting major depressive disorder studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a major depressive disorder study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a major depressive disorder trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New major depressive disorder studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.